Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLBI (interferon alfa, NAMALWA) in hepatitis C patients with compensated cirrhosis
jRCT2080220477Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of interferon alfa in hepatitis C virus infection and Cirrhosis, sponsored by Sumitomo Pharma.
02
Drugs
interferon alfa
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on jRCT2080220477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220477.